环丙沙星在囊性纤维化患者中的药代动力学及痰液穿透性
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.
作者信息
Smith M J, White L O, Bowyer H, Willis J, Hodson M E, Batten J C
出版信息
Antimicrob Agents Chemother. 1986 Oct;30(4):614-6. doi: 10.1128/AAC.30.4.614.
Abstract
Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa. Patients were studied in a steady state on a dosage of 500 mg every 8 h. Peak levels in serum ranged from 1.27 to 5.6 mg/liter (mean, 3.16 +/- 1.27), and absorption was rapid, the time to peak concentration ranging from 0.5 to 3.0 h (mean, 1.5 +/- 0.9). The antibiotic penetrated sputum well, achieving areas under the curve of approximately 46% of those obtained in serum.
摘要
对8例感染铜绿假单胞菌的囊性纤维化患者的血清和痰液中的环丙沙星水平进行了研究。患者在每8小时服用500毫克剂量的稳定状态下接受研究。血清中的峰值水平在1.27至5.6毫克/升之间（平均为3.16 +/- 1.27），吸收迅速，达到峰值浓度的时间在0.5至3.0小时之间（平均为1.5 +/- 0.9）。抗生素在痰液中渗透良好，曲线下面积约为血清中获得的曲线下面积的46%。
相似文献
1
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.环丙沙星在囊性纤维化患者中的药代动力学及痰液穿透性
Antimicrob Agents Chemother. 1986 Oct;30(4):614-6. doi: 10.1128/AAC.30.4.614.
2
3
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.环丙沙星单药治疗囊性纤维化急性肺部加重期
Am J Med. 1987 Apr 27;82(4A):174-9.
4
Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:147-52. doi: 10.1093/jac/18.supplement_d.147.
5
Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.环丙沙星治疗囊性纤维化患者铜绿假单胞菌感染急性加重期的临床和药代动力学研究
J Antimicrob Chemother. 1989 Nov;24(5):787-95. doi: 10.1093/jac/24.5.787.
6
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.环丙沙星和氧氟沙星在囊性纤维化患者中的比较药代动力学。
J Antimicrob Chemother. 1987 Oct;20(4):575-83. doi: 10.1093/jac/20.4.575.
7
Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.妥布霉素治疗囊性纤维化患者铜绿假单胞菌感染：痰液中抗生素剂量和浓度的影响
J Infect Dis. 1976 Aug;134 Suppl:S191-3. doi: 10.1093/infdis/134.supplement_1.s191.
8
Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.环丙沙星在囊性纤维化患者中的药代动力学和药效学
Antimicrob Agents Chemother. 1986 Aug;30(2):260-6. doi: 10.1128/AAC.30.2.260.
9
Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis.阿洛西林和庆大霉素用于囊性纤维化患者铜绿假单胞菌所致呼吸道感染的治疗
Scand J Infect Dis Suppl. 1981;29:64-9.
10
Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.环丙沙星吸入用干粉在囊性纤维化患者中的安全性和药代动力学：一项I期随机单剂量剂量递增研究。
J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):106-15. doi: 10.1089/jamp.2013.1056. Epub 2014 Jul 22.
引用本文的文献
1
Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.抗生素治疗囊性纤维化患者的药代动力学和药效学优化：当前证据、知识空白和未来方向。
Clin Pharmacokinet. 2021 Apr;60(4):409-445. doi: 10.1007/s40262-020-00981-0. Epub 2021 Jan 24.
2
Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.液相色谱 - 质谱联用检测囊性纤维化患者痰液中的抗生素药物
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.00927-20.
3
Clinical pharmacokinetics of inhaled antimicrobials.吸入性抗菌药物的临床药代动力学
Clin Pharmacokinet. 2015 May;54(5):473-92. doi: 10.1007/s40262-015-0250-x.
4
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.雾化抗菌药物在慢性感染性囊性纤维化患者中的药代动力学和药效学
Clin Microbiol Rev. 2014 Oct;27(4):753-82. doi: 10.1128/CMR.00022-14.
5
Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.在健康受试者中吸入环丙沙星干粉制剂：一项 I 期研究。
Clin Drug Investig. 2013 Jun;33(6):419-27. doi: 10.1007/s40261-013-0082-0.
6
Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.综述：与药物相关的口腔扩散控制释放剂型特性的计算
Eur J Drug Metab Pharmacokinet. 2010 Sep;35(1-2):29-39. doi: 10.1007/s13318-010-0005-x.
7
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.早期抗假单胞菌在年轻囊性纤维化患者中的获得：EPIC 临床试验和观察研究的原理和设计'。
Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15.
8
Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.口服控释剂型肺部组织及支气管分泌物中抗生素浓度的计算。
Inflammopharmacology. 1998;6(4):321-37. doi: 10.1007/s10787-998-0016-2.
9
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.群体药代动力学及应用蒙特卡洛模拟评估目前推荐的囊性纤维化成年患者环丙沙星给药方案
Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001.
10
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.美罗培南、亚胺培南、替莫西林、哌拉西林和头孢他啶分别与妥布霉素、利福平或环丙沙星联合应用对囊性纤维化患者分离出的洋葱伯克霍尔德菌的体外比较活性。
Antimicrob Agents Chemother. 1999 Feb;43(2):213-7. doi: 10.1128/AAC.43.2.213.
本文引用的文献
1
Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis.替卡西林与羧苄西林治疗囊性纤维化患者支气管肺感染加重期的比较。
Br J Dis Chest. 1983 Apr;77(2):179-84. doi: 10.1016/0007-0971(83)90025-6.
2
Pharmacokinetics and tissue penetration of ciprofloxacin.环丙沙星的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
3
Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.阿洛西林与羧苄西林治疗囊性纤维化患者铜绿假单胞菌所致支气管肺部感染的比较。
Thorax. 1984 Apr;39(4):299-304. doi: 10.1136/thx.39.4.299.
4
In-vitro studies with ciprofloxacin, a new 4-quinolone compound.使用新型4-喹诺酮化合物环丙沙星进行的体外研究。
J Antimicrob Chemother. 1984 Apr;13(4):333-46. doi: 10.1093/jac/13.4.333.
5
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
Zotero 插件